| Solriamfetol Hydrochloride | Axsome Therapeutics | ||
| 75, 150 mg; Tablet |
Less Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
| SUNOSI is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). | |||
|
Yes
| |||
| Sunosi | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 | Patent 32 | Patent 33 | Patent 34 | Patent 35 | Patent 36 | Patent 37 | Patent 38 | Patent 39 | Patent 40 | Patent 41 | Patent 42 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | **** ** **** **, **** | ******* **** *** | ******* **** *** | **** ** **** **, **** | ******* **** *** | **** ** **** **, **** | **** ** **** **, **** | **** ** **** **, **** | **** ** **** **, **** | **** ** **** **, **** | **** ** **** **, **** | **** ** **** **, **** | **** ** **** **, **** | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** **** **, **** (***** ******) | **** ** **** **, **** (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) |
| ********* | **** ** **** **, **** | ******* **** *** | ******* **** *** | **** ** **** **, **** | ******* **** *** | **** ** **** **, **** | ******* **** *** | ******* **** *** | **** ** **** **, **** | **** ** **** **, **** | **** ** **** **, **** | **** ** **** **, **** | ******* **** *** | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** **** **, **** (***** ******) | **** ** **** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) |
| ****** | ******* | ******* **** *** | ******* **** *** | ******* | ******* **** *** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | *** ********* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | *** ********* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | ******* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ ********* | *** **, **** | ******* | **** | *** ****** *** **** |
| ********* | *** \ ********* | *** **, **** | ******* | **** | *** ****** *** **** |
| ****** | *** \ ********* | *** **, **** | ******* | ********* ******** | ** ***** *, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|